<DOC>
	<DOCNO>NCT00005000</DOCNO>
	<brief_summary>The purpose study compare two drug ( nelfinavir [ NFV ] efavirenz [ EFV ] ) use start-up anti-HIV treatment . Doctors want see one good extending time viral load ( level HIV blood ) keep low . The study also look response immune system drug .</brief_summary>
	<brief_title>Treatment With Nelfinavir Efavirenz HIV-Infected Patients Who Have Never Received Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomized initiate therapy receive either nelfinavir ( NFV ) efavirenz ( EFV ) first regimen ( R1 ) . All patient also receive zidovudine ( AZT ) lamivudine ( 3TC ) . Patients randomize factorial fashion stratification base HIV RNA level ( less 10,000 , 10,000-100,000 , great 100,000 copies/ml ) administer single injection neo-antigen ( KLH ) Week 12 , 24 , 48 . Therapy continue switch criterion meet either Week 24 . When switch criterion meet , patient advance next regimen ( R2 ) . R2 patient previously take NFV switch EFV ; randomize EFV switch NFV ; additional NRTIs change stavudine ( d4T ) didanosine ( ddI ) . Therapy continue additional 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible trial : Are HIVpositive . Have CD4 count least 100 cells/mm3 . Have viral load least 5,000 copies/ml . Exclusion Criteria Patients may eligible study : Have take antiretroviral ( antiHIV ) agent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Lymphoid Tissue</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Genotype</keyword>
	<keyword>Phenotype</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Adipose Tissue</keyword>
	<keyword>Glucose</keyword>
	<keyword>Lipids</keyword>
	<keyword>Immunophenotyping</keyword>
	<keyword>efavirenz</keyword>
</DOC>